Clinical Trials Logo
  1. Home
  2. Primary Membranous Nephropathy
  3. NCT05800873

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Primary Membranous Nephropathy Clinical Trial

Official title:
A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

Clinical Trial Summary

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted is primary membranous nephropathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05800873
Study type Interventional
Source Everest Medicines (China) Co.,Ltd.
Contact Lixia Wang
Phone 00862180123250
Email lixia.wang@everestmedicines.com
Status Recruiting
Phase Phase 1
Start date May 15, 2023
Completion date April 15, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05514015 - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy Phase 4
Recruiting NCT05668403 - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy Phase 1
Recruiting NCT05696613 - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy Phase 3
Active, not recruiting NCT04629248 - A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Phase 3
Recruiting NCT05862233 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 3
Not yet recruiting NCT06120673 - REmission in Membranous Nephropathy International Trial (REMIT) Phase 3
Recruiting NCT05398653 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 1/Phase 2
Active, not recruiting NCT05136456 - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy Phase 2
Recruiting NCT05707377 - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy Phase 2/Phase 3